<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="570">
  <stage>Registered</stage>
  <submitdate>12/09/2005</submitdate>
  <approvaldate>16/09/2005</approvaldate>
  <actrnumber>ACTRN12605000437662</actrnumber>
  <trial_identification>
    <studytitle>Bi-level Ventilatory Support during exacerbations of Cystic Fibrosis</studytitle>
    <scientifictitle>Randomised trial of short-term effects of bi-level ventilatory support (BVS) on lung function, gas exchange, exercise capacity, quantitative sputum microbiology and quality of life during an exacerbation of Cystic Fibrosis</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil known</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Cystic Fibrosis</healthcondition>
    <conditioncode>
      <conditioncode1>Human genetics and inherited disorders</conditioncode1>
      <conditioncode2>Cystic fibrosis</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Patients will be randomised to receive BVS in combination with standard therapy or not throughout a hospital admission for an acute respiratory exacerbation. BVS will be applied when the patient is awake, as an adjunct to chest physiotherapy with a physiotherapist, and for self use for physiotherapy or dyspnoea relief.</interventions>
    <comparator>Control treatment was standard inpatient therapy throughout a hospital admission for an acute respiratory exacerbation</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Rate of improvement in daily lung function and symptom severity scores. </outcome>
      <timepoint>Measured daily</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Absolute improvement in lung function and symptom severity scores for admission and discharge.</outcome>
      <timepoint>At admission and discharge.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Exercise capacity</outcome>
      <timepoint>Admission, discharge.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quantitative sputum microbiology</outcome>
      <timepoint>Admission, day 6, discharge.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of life</outcome>
      <timepoint>Admission, discharge.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Dyspnoea</outcome>
      <timepoint>Admission, day 6, discharge.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Arterial blood gas</outcome>
      <timepoint>Admission, discharge.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Respiratory muscle strength</outcome>
      <timepoint>Admission, day 1, day 6, discharge.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Oxygen saturation, heart rate, respiratory rate post physiotherapy</outcome>
      <timepoint>Day 1, day 6, discharge.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to next hospital re-admission.</outcome>
      <timepoint>Next hospital re-admission recorded/measured on admission to hospital for an acute exacerbation of cystic fibrosis (i.e. "time to event" data).</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Acute respiratory exacerbation of Cystic Fibrosis (Fuchs et al 1994) requiring IV antibiotics and admission to hospital; aged over 17 years; FEV1 &lt;60% predicted on admission.</inclusivecriteria>
    <inclusiveminage>17</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Already using BVS or daytime respiratory failure on admission; problem pneumothoraces; recent massive haemoptysis; pregnant; sputum colonised with burkolderia cepacia; previous participation in this study; admitted for lung transplant work-up.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Sealed opaque envelopes</concealment>
    <sequence>Computer-generated randomisation table. Block randomisation</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>1/10/2003</anticipatedstartdate>
    <actualstartdate>9/10/2003</actualstartdate>
    <anticipatedenddate />
    <actualenddate>14/06/2006</actualenddate>
    <samplesize>40</samplesize>
    <actualsamplesize>40</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>SWSAHS</primarysponsorname>
    <primarysponsoraddress>Level 11, KGV Building
Missenden Road
Camperdown NSW 2050</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>NHMRC Progress Grant</fundingname>
      <fundingaddress>Director, Research Administration Section
National Health and Medical Research Council
GPO Box 1421
Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>None</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This trial was completed recruitment in 2006 and data collection (for time-to-next readmission in 2015. Manuscript was published in the Journal of Physiotherapy 2015, vol 61:142-147.</summary>
    <trialwebsite />
    <publication>Dwyer TJ, Robbins L, Kelly P, Piper AJ, Bell S, Bye PTP. Non-invasive ventilation used as an adjunct to airway clearance treatments improves lung function during an acute exacerbation of cystic fibrosis: a randomised trial. Journal of Physiotherapy. 2015;61:142-147</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Prince Alfred Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>8/09/2003</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Prince Charles Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>11/12/2003</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Peter Bye</name>
      <address>Department of Respiratory Medicine
Royal Prince Alfred Hospital
11 West
Missenden Road
Camperdown NSW 2050</address>
      <phone>+61 2 95157427</phone>
      <fax>+61 2 95158196</fax>
      <email>peterb@med.usyd.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Tiffany Dwyer</name>
      <address>Department of Respiratory Medicine
Royal Prince Alfred Hospital
11 West
Missenden Road
Camperdown NSW 2050</address>
      <phone>+61 2 95155234</phone>
      <fax>+61 2 95158196</fax>
      <email>tdwyer@med.usyd.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Tiffany Dwyer</name>
      <address>Respiratory Medicine
Level 11
RPA Hospital
Missenden Rd
Camperdown NSW 2050</address>
      <phone>61 2 9515 5234</phone>
      <fax />
      <email>tiffany.dwyer@sydney.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>